InsidersTradesSigma
Track the Senseonics Holdings, Inc. stock price and the full directors' dealings record of the company, a listed equity based in United States. Shares are quoted on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Senseonics Holdings, Inc. has recorded 99 reports. Market capitalisation: €266.8m. The latest transaction was filed on 5 January 2026 (Attribution). Among the most active insiders: JAIN Mukul. All data is accessible without an account.
99
Insider Decl.
n/a
Thresholds
€247,500
4 ops.
Buy Volume
€1m
8 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Senseonics Holdings, Inc. Buy (bullish), based on 5 analysts. Average price target: US$13.40.
57Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 26,189 of 29,064 companies
21.8
score / 100
Value11
Quality32
FCF yld-16%
Earn yld-19%
EV/EBITDA·
ROE-118%
Gross mgn45%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 5 January 2026
Declarations99 total
2,504 shares@ US$5.891.8% of flowCommon StockSEC:0001270735-26-000002:0
2,185 shares@ US$5.894.0% of flowCommon StockSEC:0001683354-26-000002:0
1,379 shares@ US$5.892.7% of flowCommon StockSEC:0001666995-26-000002:0
2,398 shares@ US$5.894.4% of flowCommon StockSEC:0001666972-26-000002:0
6,402 shares@ US$6.2655.6% of flowCommon StockSEC:0001944539-25-000006:0
4,605 shares@ US$6.264.7% of flowCommon StockSEC:0001769791-25-000004:0
10,317 shares@ US$6.267.1% of flowCommon StockSEC:0001667593-25-000004:0
27,067 shares@ US$6.267.4% of flowCommon StockSEC:0001667588-25-000006:0
5,997 shares@ US$6.2610.0% of flowCommon StockSEC:0001552047-25-000003:0
10,000 shares@ US$6.5521.8% of flowCommon StockSEC:0001683354-25-000006:0
Canonical exit: 8 Feb 2026 (T+90)
5,415 shares@ US$5.88100.0% of flowCommon StockSEC:0001944539-25-000004:0
Canonical exit: 5 Feb 2026 (T+90)
17,210 shares@ US$5.874.8% of flowCommon StockSEC:0001667588-25-000004:0
Canonical exit: 5 Feb 2026 (T+90)
15,000 shares@ US$5.8310.9% of flowCommon StockSEC:0001270735-25-000006:0
Canonical exit: 5 Feb 2026 (T+90)
842,084 shares0Common StockSEC:0001415889-25-014860:0
111,386 shares0Common StockSEC:0001415889-25-014715:0
111,386 shares0Common StockSEC:0001415889-25-014717:0
2,025,956 shares0Common StockSEC:0001415889-25-014710:0
505,251 shares0Common StockSEC:0001415889-25-014713:0
990,688 shares0Common StockSEC:0001415889-25-014712:0
455,716 shares0Common StockSEC:0001415889-25-014714:0
111,386 shares0Common StockSEC:0001415889-25-014720:0
111,386 shares0Common StockSEC:0001415889-25-014722:0
111,386 shares0Common StockSEC:0001415889-25-014716:0
693,481 shares0Common StockSEC:0001415889-25-014711:0
111,386 shares0Common StockSEC:0001415889-25-014718:0
25 of 99 declarations
关于 Senseonics Holdings, Inc.
Senseonics Holdings, Inc. 是一家总部位于美国的医疗技术公司，在美国纳斯达克上市。该公司成立于1996年，总部位于马里兰州日耳曼敦，专注于开发和商业化用于糖尿病患者的连续血糖监测 (CGM) 系统。其商业模式以可植入、长效血糖传感器为中心，这使其在 CGM 市场中相对于更传统的外部或频繁更换的传感器系统具有差异化优势。（[stockanalysis.com](https://stockanalysis.com/stocks/sens/company/?utm_source=openai)） 该公司的核心平台是 Eversense 系列产品，包括 Eversense E3 和 Eversense 365。Senseonics 将这些产品描述为长期植入式 CGM 系统，旨在通过易用性、准确性和监测连续性来改善糖尿病管理。在其2025年年度报告中，该公司指出，在2024年10月推出 Eversense 365 后，其直接面向消费者的潜在客户增加，患者出货量增加，并在2025年12月达到了公司历史上最高的月度出货量。这些数据点表明商业吸引力正在改善，尽管与最大的 CGM 同行相比，该公司仍处于早期阶段。（[sec.gov](https://www.sec.gov/Archives/edgar/data/0001616543/000110465926022298/sens-20251231x10k.htm?utm_source=openai)） 从竞争角度来看，Senseonics 在一个由规模更大、商业规模更广、资源更深厚的糖尿病技术公司主导的市场中运营。其竞争优势主要在于技术和临床差异化：一种具有延长佩戴时间的可植入传感器、独特的患者体验以及可能吸引某些患者和提供者的利基定位。与此同时，该公司仍然是一个相对较小的成长型公司，其执行风险与报销、医生采纳、制造和销售团队效率相关。（[stockanalysis.com](https://stockanalysis.com/stocks/sens/company/?utm_source=openai)） 近期发展对投资者尤为重要。Senseonics 表示，从2026年1月1日起，它将接管美国的商业化和分销业务，这一战略转变使得销售和营销工作内部化。该公司2025年的文件还指出，Eversense 365 在欧洲的监管工作正在进行中，并且在推出后产品势头持续。对于讲法语的投资者而言，SENS 因此是一家在纳斯达克上市的美国医疗保健小型股，对 CGM 的采纳具有吸引力的长期主题性敞口，但存在需要密切关注的重大运营、监管和融资风险。（[sec.gov](https://www.sec.gov/Archives/edgar/data/0001616543/000110465926022298/sens-20251231x10k.htm?utm_source=openai)）
